文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹自身免疫性与大疱性皮肤病

系统用钙调神经磷酸酶抑制剂他克莫司与伏环孢素:皮肤科超说明书应用综述

Systemic calcineurin inhibitors tacrolimus and voclosporin: A review of off-label dermatologic uses.
PubMed 文献 · J Am Acad Dermatol · 2023-06-10

本文综述系统用他克莫司与伏环孢素在多种皮肤病中的超说明书应用。他克莫司在银屑病、特应性皮炎/湿疹、坏疽性脓皮病、慢性荨麻疹及白塞病中显示潜力;伏环孢素仅有银屑病随机对照试验数据,显示有效但未达到非劣于环孢素。与环孢素相比,他克莫司可考虑用于难治性疾病或伴心血管危险因素或炎症性肠病患者;伏环孢素目前仅用于银屑病,可考虑用于狼疮肾炎患者。

要点

  • 他克莫司在银屑病、特应性皮炎/湿疹、坏疽性脓皮病、慢性荨麻疹及白塞病中显示潜力。
  • 伏环孢素仅有银屑病随机对照试验数据,显示有效但未达到非劣于环孢素。
  • 与环孢素相比,他克莫司可考虑用于难治性疾病或伴心血管危险因素或炎症性肠病患者。

核心结论

  • 与环孢素相比,他克莫司可考虑用于治疗难治性疾病或伴有心血管危险因素或炎症性肠病的患者。
  • 伏环孢素目前仅用于银屑病,其临床试验显示有效;伏环孢素可考虑用于狼疮肾炎患者。

研究设计与样本

  • 通过PubMed和Google Scholar进行文献检索,纳入关于系统用他克莫司和伏环孢素超说明书皮肤科应用的相关临床试验、观察性研究、病例系列和病例报告。

主要发现

  • 他克莫司在多种皮肤病中显示潜力,包括银屑病、特应性皮炎/湿疹、坏疽性脓皮病、慢性荨麻疹和白塞病。
  • 随机对照试验数据仅见于伏环孢素治疗银屑病,显示有效但未达到非劣于环孢素。

临床怎么用

  • 与环孢素相比,他克莫司可考虑用于治疗难治性疾病或伴有心血管危险因素或炎症性肠病的患者。
  • 伏环孢素目前仅用于银屑病,可考虑用于狼疮肾炎患者。

局限性

  • 数据有限且提取自已发表论文。
  • 研究方法不同,非标准化结局限制了得出的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic calcineurin inhibitors, cyclosporine, tacrolimus, and voclosporin, have been utilized in various dermatologic conditions. Although there have been numerous off-label dermatologic indications with published guidelines for cyclosporine, there is no established strong consensus for tacrolimus and voclosporin. OBJECTIVE: To conduct a review of off-label use of systemic tacrolimus and voclosporin in various dermatoses to better inform treatment methods. METHODS: A literature search was conducted using PubMed and Google Scholar. Relevant clinical trials, observational studies, case series, and reports regarding off-label dermatologic uses of systemic tacrolimus and voclosporin were included. RESULTS: Tacrolimus shows promise for numerous dermatologic conditions, including psoriasis, atopic dermatitis/eczema, pyoderma gangrenosum, chronic urticaria, and Behcet's disease. Randomized controlled trial data are only available for voclosporin in psoriasis, which showed efficacy but did not meet noninferiority to cyclosporine. LIMITATIONS: Data were limited and extracted from published papers. Studies differed in methodology, and nonstandardized outcomes limited the conclusions drawn. CONCLUSIONS: In comparison to cyclosporine, tacrolimus can be considered for treatment-refractory disease or in patients with cardiovascular risk factors or inflammatory bowel disease. Voclosporin has only been utilized in psoriasis currently, and clinical trials in psoriasis show voclosporin's efficacy. Voclosporin can be considered for patients with lupus nephritis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Dai A, Kim SJ. Systemic calcineurin inhibitors tacrolimus and voclosporin: A review of off-label dermatologic uses. J Am Acad Dermatol. 2023. PMID: 37307993. doi:10.1016/j.jaad.2023.05.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。